follow-up results for ruxolitinib in the second-line treatment of pv
Published 6 years ago • 58 plays • Length 1:10Download video MP4
Download video MP3
Similar videos
-
1:32
response-2: 5-year follow-up of second-line ruxolitinib therapy for pv
-
1:13
updated findings after 5-year follow-up for ruxolitinib in pv
-
0:31
exploring the benefits of ruxolitinib in second-line polycythemia vera
-
4:52
treating pv with jak inhibition now and in the future
-
3:45
ruxolitinib as second-line therapy in polycythemia vera
-
1:46
results for the follow-up of the response study
-
1:40
understanding the role of ruxolitinib in patients with polycythemia vera
-
2:09
majic update: promising results for ruxolitinib in pv and et
-
5:50
case 2: the response trial of ruxolitinib for pv
-
4:17
pv: treatment with ruxolitinib
-
3:07
further analysis of response trial data validates ruxolitinib as second-line therapy
-
5:36
case 2: ruxolitinib treatment for polycythemia vera
-
4:43
the role of ruxolitinib in treating polycythemia vera
-
1:27
insights into the reveal trial: the efficacy of ruxolitinib for the treatment of patients with pv
-
1:23
response-2 5-year follow-up update: ruxolitinib vs bat in polycythemia vera without splenomegaly
-
19:03
assessment of novel treatment options for patients with pv
-
1:44
follow up of the phase 3 response trial of ruxolitinib in polycythemia vera
-
6:07
available treatment options for patients with pv
-
4:42
response-2 trial: ruxolitinib for pv